Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 558
Filter
1.
Singapore medical journal ; : 16-22, 2024.
Article in English | WPRIM | ID: wpr-1007300

ABSTRACT

INTRODUCTION@#The use of periarticular (PA) tranexamic acid (TXA) and its efficacy in comparison with intra-articular (IA) TXA have not been well explored in the literature. This retrospective cohort study aimed to compare the effects of IA and PA TXA with analgesic components in reducing blood loss and improving immediate postoperative pain relief and functional outcomes in patients after unilateral primary total knee arthroplasty (TKA).@*METHODS@#A total of 63 patients underwent TKA, and they were divided into the IA TXA delivery group ( n = 42) and PA TXA delivery group ( n = 21). All patients were administered 1 g of TXA. They also received pericapsular infiltration consisting of 0.5 mL of adrenaline, 0.4 mL of morphine, 1 g of vancomycin, 1 mL of ketorolac and 15 mL of ropivacaine. Outcomes for blood loss and surrogate markers for immediate functional recovery were measured.@*RESULTS@#Of the 63 patients, 54% were female and 46% male. The mean drop in postoperative haemoglobin levels in the PA and IA groups was 2.0 g/dL and 1.6 g/dL, respectively, and this was not statistically significant ( P = 0.10). The mean haematocrit drop in the PA and IA groups was 6.1% and 5.3%, respectively, and this was also not statistically significant ( P = 0.58). The postoperative day (POD) 1 and discharge day flexion angles, POD 1 and POD 2 visual analogue scale (VAS) scores, gait distance on discharge and length of hospitalisation stay were largely similar in the two groups.@*CONCLUSION@#Our study showed that both IA and PA TXA with analgesic components were equally efficient in reducing blood loss and improving immediate postoperative pain relief and functional outcomes.


Subject(s)
Humans , Male , Female , Tranexamic Acid/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Antifibrinolytic Agents/adverse effects , Retrospective Studies , Postoperative Hemorrhage , Blood Loss, Surgical/prevention & control , Administration, Intravenous , Analgesia , Analgesics/therapeutic use , Pain, Postoperative/drug therapy , Injections, Intra-Articular
2.
Cogitare Enferm. (Online) ; 28: e88604, Mar. 2023. tab, graf
Article in Portuguese | LILACS, BDENF | ID: biblio-1514037

ABSTRACT

RESUMO Objetivo: demonstrar a aplicabilidade da ferramenta Healthcare Failure Mode and Effect Analysis para analisar, preventivamente, os riscos relativos ao processo de inserção, manutenção e retirada de cateter intravenoso periférico. Método: estudo teórico, realizado de agosto a novembro de 2022, em São Paulo-SP, Brasil, cujo processo foi mapeado em etapas/atividades, detalhando-se os modos de falha, com o uso da ferramenta. Calculou-se o Risk Priority Number, elaborou-se a matriz de severidade e probabilidade, adaptada à saúde por DeRosier e colaboradores, e propuseram-se as ações para reduzir os modos de falha. Resultados: identificaram-se como maiores riscos: "realizar antissepsia da área a ser puncionada com swab de álcool" e "desinfecção do conector com swab de álcool" sendo recomendados treinamentos e uso de kit de materiais como principais estratégias de mitigação. Conclusão: conhecer os riscos associados ao cateter intravenoso periférico, fundamenta a implementação de estratégias preventivas, minimizando a ocorrência de danos e os custos assistenciais deles decorrentes.


ABSTRACT Objective: to demonstrate the applicability of the Healthcare Failure Mode and Effect Analysis tool to analyze, preventively, the risks related to the process of insertion, maintenance, and removal of peripheral intravenous catheters. Method: theoretical study, conducted from August to November 2022, in São Paulo-SP, Brazil, whose process was mapped in stages/activities, detailing the failure modes, using the tool. The Risk Priority Number was calculated, the severity and probability matrix was elaborated, adapted to health by DeRosier and collaborators, and actions were proposed to reduce failure modes. Results: The major risks identified were: "perform antisepsis of the area to be punctured with an alcohol swab" and "disinfect the connector with an alcohol swab", and were recommended training and use of kit materials as the main mitigation strategies. Conclusion: knowing the risks associated with peripheral intravenous catheters is the basis for the implementation of preventive strategies, minimizing the occurrence of damage and the associated healthcare costs.


RESUMEN Objetivo: demostrar la aplicabilidad de la herramienta Healthcare Failure Mode and Effect Analysis para analizar, de forma preventiva, los riesgos relacionados con el proceso de inserción, mantenimiento y retirada de catéteres intravenosos periféricos. Método: estudio teórico, realizado de agosto a noviembre de 2022, en São Paulo-SP, Brasil, cuyo proceso fue mapeado en etapas/actividades, detallando los modos de falla, utilizando la herramienta. Se calculó el Número de Prioridad de Riesgo, se elaboró la matriz de severidad y probabilidad, adaptada a la salud por DeRosier y colaboradores, y se propusieron acciones para reducir los modos de falla. Resultados: Los principales riesgos identificados fueron: "realizar la antisepsia de la zona a puncionar con un bastoncillo con alcohol" y "desinfectar el conector con un bastoncillo con alcohol", recomendándose como principales estrategias de mitigación la formación y el uso de kits de materiales. Conclusión: Conocer los riesgos asociados al catéter intravenoso periférico sienta las bases para la aplicación de estrategias preventivas, minimizando la aparición de daños y los costes sanitarios derivados de los mismos.


Subject(s)
Risk Management , Catheterization , Administration, Intravenous
3.
Arq. ciências saúde UNIPAR ; 27(3): 1269-1283, 2023.
Article in Portuguese | LILACS | ID: biblio-1425965

ABSTRACT

Introdução: A terapia com medicamentos endovenosos é muito utilizada nas unidades hospitalares, porém, possui uma elevada chance de incidentes, principalmente quando os medicamentos são administrados simultaneamente em via Y. Essa prática pode resultar em incompatibilidades medicamentosas classificadas em reações físicas e químicas. Objetivo: Construir e validar uma ferramenta preventiva de incompatibilidade medicamentosa em via Y. Método: Estudo metodológico com abordagem quantitativa. Foi desenvolvido em três etapas: Levantamento bibliográfico, construção e diagramação do material e por fim, a validação da ferramenta preventiva. Para validação, a ferramenta preventiva foi submetida ao processo de validação de face e conteúdo por juízes com expertise na temática. Resultados: Construiu-se e validou-se uma ferramenta preventiva através da busca de dados na literatura com a participação de sete juízes especialistas na temática. Os itens avaliativos referentes a tabela de incompatibilidade medicamentosa quanto aos objetivos, estrutura, apresentação e relevância da ferramenta preventiva foi considerada válida, pois foram julgados como adequado pelos especialistas. Conclusão: A validação de conteúdo, foi considerada válida pelos juízes, portanto, espera-se que o material alcance o seu objetivo ao ser aplicado durante a prática clínica. Dessa forma, será disponibilizado à instituição para que seja utilizado, favorecendo a prevenção de danos e contribuindo para a segurança dos pacientes, bem como melhorando a qualidade da assistência e educação em saúde.


Introduction: Intravenous drug therapy is widely used in hospital units, however, it has a high chance of incidents, especially when drugs are administered simultaneously in a Y route. This practice can result in drug incompatibilities classified into physical and chemical reactions. Objective: To build and validate a preventive tool for drug incompatibility in the Y pathway. Method: Methodological study with a quantitative approach. It was developed in three stages: bibliographic survey, construction and layout of the material and finally, the validation of the preventive tool. For validation, the preventive tool was submitted to the face and content validation process by judges with expertise in the subject. Results: A preventive tool was built and validated through the search for data in the literature with the participation of seven expert judges on the subject. The evaluative items referring to the medication incompatibility table regarding the objectives, structure, presentation and relevance of the preventive tool were considered valid, as they were judged as adequate by the specialists. Conclusion: The content validation was considered valid by the judges, therefore, it is expected that the material reaches its objective when applied during clinical practice. In this way, it will be made available to the institution for use, favoring the prevention of damage and contributing to patient safety, as well as improving the quality of health care and education.


Introducción: La farmacoterapia intravenosa es ampliamente utilizada en las unidades hospitalarias, sin embargo, tiene una alta probabilidad de incidencias, especialmente cuando los fármacos se administran simultáneamente en una vía Y. Esta práctica puede dar lugar a incompatibilidades medicamentosas clasificadas en reacciones físicas y químicas. Objetivo: Construir y validar una herramienta preventiva de incompatibilidad de medicamentos en la vía Y. Método: Estudio metodológico con enfoque cuantitativo. Se desarrolló en tres etapas: relevamiento bibliográfico, construcción y diagramación del material y finalmente, la validación de la herramienta preventiva. Para la validación, la herramienta preventiva fue sometida al proceso de validación facial y de contenido por jueces expertos en el tema. Resultados: Se construyó y validó una herramienta preventiva a través de la búsqueda de datos en la literatura con la participación de siete jueces expertos en el tema. Los ítems evaluativos referentes a la tabla de incompatibilidad de medicamentos en relación a los objetivos, estructura, presentación y relevancia de la herramienta preventiva fueron considerados válidos, pues fueron juzgados como adecuados por los especialistas. Conclusiones: La validación del contenido fue considerada válida por los jueces, por lo tanto, se espera que el material alcance su objetivo al ser aplicado durante la práctica clínica. De esta forma, se pondrá a disposición de la institución para su uso, favoreciendo la prevención de daños y contribuyendo a la seguridad del paciente, además de mejorar la calidad de la atención y educación en salud.


Subject(s)
Laboratory Equipment , Drug Incompatibility , Disease Prevention , Administration, Intravenous/instrumentation , Pharmaceutical Preparations , Health Education , Health Personnel/organization & administration , Validation Studies as Topic , Patient Safety , Anti-Infective Agents/pharmacology
4.
Braz. J. Pharm. Sci. (Online) ; 59: e22643, 2023. tab, graf
Article in English | LILACS | ID: biblio-1439528

ABSTRACT

Abstract Methotrexate on its oral and intravenous administration results in unwanted adverse effects. This drawback can be overcome by transdermal delivery because of its painless objective for systemic drug administration. Transfersomes are ultra-deformable vesicles with the flexibility to reach deeper tissues of the skin. The objective of this research work was to develop methotrexate transfersomal gel by thin film hydration technique, evaluated for entrapment efficiency, deformability, mean vesicle size, and stability, and incorporated into carbopol gel for ease of handling and skin applicability for a longer period of retention on skin. MTX-TFS gel & conventional gel were characterized for consistency, transparency, viscosity, and pH. Ex-vivo skin permeation studies were performed using abdominal goat skin and drug release kinetic parameters and transdermal flux were calculated using mathematical models. The results indicate that MTX was successfully entrapped (84.77 ± 2.35 %w/w) in transfersomes having 240±1.6 nm vesicle sizes and 27.13±0.7 deformability index. The gel was permeated through the skin at a rate of 28.12±2.58 µg/cm2/hr as compared to the conventional gel (10.35±2.14 µg/cm2/ hr). From the study, it was concluded that the MTX-TFS gel can be used as a possible substitute for the conventional formulation for transdermal drug delivery due to 3 times improvement in transdermal flux.


Subject(s)
Administration, Cutaneous , Methotrexate/adverse effects , Skin , Administration, Intravenous/classification
5.
Article in Portuguese | LILACS, BDENF | ID: biblio-1442411

ABSTRACT

Objetivo: Implantar um time de terapia intravenosa em um hospital de grande porte. Método: Estudo de abordagem qualitativa realizado a partir de encontros de grupo de convergência, utilizando o referencial metodológico da pesquisa convergente-assistencial. Foram realizadas entrevis-tas semiestruturadas, a apuração dos dados obtidos por meio da análise de conteúdo e a formação de três categorias, que originaram os assuntos para a capacitação dos profissionais. Resultados: Participaram nove enfermeiros e, após a realização de quatro encontros de capacitação, foi implantado um time de terapia intravenosa e desenvolvido documento norteador para a execução do trabalho. Conclusão: O estudo resultou na implantação do time de terapia intravenosa em um hospital de grande porte a partir da pesquisa desenvolvida e da experiência de trabalho dos enfermeiros que atuam na prá-tica assistencial. O referencial metodológico possibilitou aos enfermeiros serem ouvidos enquanto promotores da ação e implementadores da inovação.Palavras-chave: Infecção hospitalar. Cateteres de demora. Infecções relacionadas a cateteres. Segurança do paciente.


Objective: To implement an intravenous therapy team in a large hospital. Method: Qualitative study carried out based on convergence group meetings, using the methodological framework of convergent-assistance research. Semi-structured interviews were carried out, data were collected through content analysis and three categories were formed, which originated the subjects for the training of professionals. Results: Nine nurses par-ticipated in the research and, after four training meetings, an intravenous therapy team was implemented and a guiding document was developed for carrying out the work. Conclusion: The study resulted in the implementation of an intravenous therapy team in a large hospital based on the research developed and the work experience of nurses who work in care practice. The methodological framework allowed nurses to be heard as promoters of action and implementers of innovation.


Objetivo: Implementar un equipo de terapia intravenosa en un gran hospital. Método: Estudio cualitativo realizado a partir de reuniones de grupos de convergencia, utilizando el marco metodológico de investigación convergente-asistencial. Fueron realizadas entrevistas semiestructuradas, reco-gida de datos a través del análisis de contenido y la formación de tres categorías, que originaron los temas para la formación de profesionales. Resultados:Participaron nueve enfermeros y, después de cuatro reuniones de capacitación, se implementó un equipo de terapia intravenosa y se elaboró un docu-mento guía para la realización del trabajo. Conclusión: El estudio resultó en la implementación de un equipo de terapia intravenosa en un hospital de gran porte a partir de la investigación desarrollada y la experiencia laboral de los enfermeros que actúan en la práctica asistencial. El marco metodológico permitió que los enfermeros sean escuchados como promotores de la acción e implementadores de la innovación.


Subject(s)
Humans , Male , Female , Adult , Catheterization, Central Venous , Patient Safety , Administration, Intravenous , Central Venous Catheters , Inservice Training , Nursing Care , Qualitative Research
6.
Rev. med. Chile ; 150(9): 1214-1223, sept. 2022. tab, graf, ilus
Article in Spanish | LILACS | ID: biblio-1431884

ABSTRACT

Severe metabolic acidosis is defined by a pH < 7.2 with HCO3− < 8 mE- q/L in plasma. Its best treatment is to correct the underlying cause. However, acidemia produces multiple complications such as resistance to the action of catecholamines, pulmonary vasoconstriction, impaired cardiovascular function, hyperkalemia, immunological dysregulation, respiratory muscle fatigue, neurological impairment, cellular dysfunction, and finally, it contributes to multisystemic failure. Intravenous NaHCO3 buffers severe acidemia, preventing the associated damage and gains time while the causal disease is corrected. Its indication requires a risk-benefit assessment, considering its complications. These are hypernatremia, hypokalemia, ionic hypocalcemia, rebound alkalosis, and intracellular acidosis. For this reason, therapy must be "adapted" and administered judiciously. The patient will require monitoring with serial evaluation of the internal environment, especially arterial blood gases, plasma electrolytes, and ionized calcium. Isotonic solutions should be preferred instead of hypertonic bicarbonate. The development of hypernatremia must be prevented, calcium must be provided for hypocalcemia to improve cardiovascular function. Furthermore, in mechanically ventilated patients, a respiratory response similar to the one that would develop physiologically, must be established to be able to extract excess CO2 and thus avoid intracellular acidosis. It is possible to estimate the bicarbonate deficit, speed, and volume of its infusion. However, the calculations are only for reference. More important is to start intravenous NaHCO3 when needed, administer it judiciously, manage its side effects, and continue it to a safe goal. In this review we address all the necessary elements to consider in the administration of intravenous NaHCO3, highlighting why it is the best buffer for the management of severe metabolic acidosis.


Subject(s)
Humans , Acidosis/drug therapy , Sodium Bicarbonate/administration & dosage , Sodium Bicarbonate/adverse effects , Severity of Illness Index , Risk Assessment , Administration, Intravenous
8.
urol. colomb. (Bogotá. En línea) ; 31(1): 41-42, 15/03/2022.
Article in Spanish | LILACS, COLNAL | ID: biblio-1368852

ABSTRACT

Los agentes antifibrinolíticos, como el ácido tranexámico, por medio de su administración endovenosa se usan en distintos procedimientos quirúrgicos para prevenir la pérdida de sangrado perioperatorio.[1] Este medicamento es un derivado sintético análogo de la lisina que bloquea los sititos de unión de la lisina en el plasminógeno, inhibiendo su conversión a plasmina e interfiriendo en la fibrinólisis.[2] La aplicación del ácido tranexámico para disminuir el riesgo de sangrado ha sido utilizado en procedimientos urológicos como la resección transuretral prostática (RTUP), prostatectomía radical y nefrolitotomía percutánea (NLP),[3] [4] [5] también se emplea para disminuir las hematurias persistentes en pacientes con poliquistosis renal y en otras hematurias macroscópicas de origen urológico.


Antifibrinolytic agents, such as tranexamic acid, by intravenous administration are used in various surgical procedures to prevent perioperative bleeding loss.[1] This drug is a synthetic lysine analog derivative that blocks the lysine binding sites on plasminogen, inhibiting its conversion to plasmin and interfering with fibrinolysis.[2] The application of tranexamic acid to reduce the risk of bleeding has been used in urological procedures such as transurethral resection of the prostate (TURP), radical prostatectomy and nephrolithotomy. The application of tranexamic acid to reduce the risk of bleeding has been used in urological procedures such as transurethral resection of the prostate (TURP), radical prostatectomy and percutaneous nephrolithotomy (PNL),[3] [4] [5] it is also used to reduce persistent hematuria in patients with polycystic kidney disease and other macroscopic hematuria of urological origin.


Subject(s)
Humans , Male , Plasminogen , Surgical Procedures, Operative , Fibrinolysin , Transurethral Resection of Prostate , Nephrolithotomy, Percutaneous , Antifibrinolytic Agents , Prostatectomy , Tranexamic Acid , Pharmaceutical Preparations , Administration, Intravenous , Polycystic Kidney Diseases , Lysine
9.
Int. j. morphol ; 40(1): 143-147, feb. 2022. ilus
Article in English | LILACS | ID: biblio-1385578

ABSTRACT

SUMMARY: Multiple sclerosis is a demyelinating disease of the nervous system that affects young people of working age and quickly leads to disability. Treatment of this pathology with umbilical cord mesenchymal stem cells is promising, given their immunomodulatory and neurotrophic properties. The study involved 27 patients diagnosed with multiple sclerosis, 12 of whom underwent combined treatment (intravenous and intrathecal administration) of umbilical cord multipotent mesenchymal stromal/stem cells. The effectiveness of treatment was determined by the degree of neurological deficit and spasticity. Combined treatment with umbilical cord mesenchymal stem cells significantly improves the condition of patients with multiple sclerosis and promotes the regression of neurological deficits and spasticity. This treatment is safe, but for a deeper study, it is necessary to continue research in this area.


RESUMEN: La esclerosis múltiple es una enfermedad desmielinizante del sistema nervioso que afecta a los jóvenes en edad laboral y conduce rapidamente a la discapacidad. El tratamiento de esta patología con células madre mesenquimales de cordón umbilical es prometedor, debido a sus propiedades inmunomoduladoras y neurotróficas. En el estudio participaron 27 pacientes diagnosticados de esclerosis múltiple, 12 de los cuales fueron sometidos a un tratamiento combinado (administración intravenosa e intratecal) de células madre / estromales mesenquimales multipotentes del cordón umbilical. La efectividad del tratamiento estuvo determinada por el grado de déficit neurológico y espasticidad. El tratamiento combinado con células madre mesenquimales del cordón umbilical mejora significativamente la condición de los pacientes con esclerosis múltiple y promueve la regresión de los déficits neurológicos y la espasticidad. Este tratamiento es seguro, sin embargo, es necesario continuar investigando en esta area.


Subject(s)
Humans , Male , Female , Adult , Umbilical Cord/cytology , Mesenchymal Stem Cells , Multiple Sclerosis/therapy , Treatment Outcome , Combined Modality Therapy , Administration, Intravenous
10.
Rev. bras. ciênc. vet ; 29(1): 3-8, jan./mar. 2022. il.
Article in Portuguese | LILACS, VETINDEX | ID: biblio-1393181

ABSTRACT

A ocorrência de processos fisiopatológicos que cursam com desidratação da ingesta no trato gastrointestinal dos equinos é comum na rotina clínica. Fatores como diminuição da motilidade intestinal e sobrecarga intraluminal de conteúdo desidratado podem levar a compactação em segmentos como estômago, ceco e cólons. Este estudo objetivou realizar a comparação entre soluções eletrolíticas enterais hipotônica (SeHIPO) e isotônica (SeISO) e a solução Ringer com lactato de sódio (RL IV) sobre o teor de umidade das fezes de equinos submetidos a um período de desidratação experimental (PD). Foram utilizados seis equinos adultos, todas fêmeas com idades entre 10 e 15 anos, média de 440 kg de peso corpóreo. O PD constou de 36 horas de jejum hídrico e alimentar associadas a duas administrações intravenosas de furosemida, sendo a primeira imediatamente no início (T-36) e a segunda 12 horas após o início do PD. Os tratamentos utilizados foram: SeHIPO e SeISO, ambas administradas por via nasogástrica em fluxo contínuo (HETfc), e RL IV administrada pela via intravenosa. Todos os tratamentos foram administrados a uma taxa de infusão contínua de 15mL kg-1 h-1 durante 8 horas consecutivas. O delineamento experimental utilizado foi o crossover6x3, onde cada animal foi submetido, em sistema de rodízio, aos três tratamentos em momentos distintos. As soluções eletrolíticas enterais demonstraram maior eficácia na recomposição do teor de umidade das fezes quando comparadas à terapia RL IV. A hidratação enteral com soluções isotônicas e hipotônicas administrada em fluxo contínuo são eficazes em restaurar o teor de umidade das fezes, podendo ofertar uma opção econômica, segura e eficiente na reidratação de pacientes e nas afecções que cursam como obstruções intraluminais simples.


The occurrence of pathophysiological processes that curse with digesta dryness in the gastrointestinal tract of horses is common in clinical routine, factors such as decreased intestinal motility and intraluminal overload of dry content can lead to compaction in segments such as cecum and colon. This study aimed to compare a hypotonic enteral solution (SeHIPO), an isotonic enteral solution (SeISO) and a Ringer with sodium lactate solution (RL IV) over the moisture content of equine feces submitted to an experimental dehydration protocol. Six adult horses were used, all females aged between 10 and 15 years, average body weight of 440 kg. The PD consisted of a 36 hours period of water and food fasting associated with two intravenous administrations of furosemide, the first immediately at the beginning (T-36) and the second 12 hours after the beginning of the PD. The treatments used were: SeHIPO (hypotonic enteral solution administered via nasogastric), SeISO (enteral isotonic solution administered via nasogastric) and RL IV (Ringer's solution with sodium lactate administered intravenously), all treatments were administered by continuous infusion at a rate of 15mL kg-1 h-1 for 8 consecutive hours. The experimental design used was the 6x3 crossover, where each animal is submitted, in a rotation system, to the three treatments at different times. Enteral fluid therapy with isotonic and hypotonic solutions administered in continuous flow are effective in restoring the moisture content of feces, and may offer an economical, safe, and efficient option for rehydrating patients and in conditions that progress as simple intraluminal obstructions.


Subject(s)
Animals , Water-Electrolyte Balance , Dehydration/veterinary , Fluid Therapy/veterinary , Ringer's Lactate/therapeutic use , Horses/metabolism , Hypotonic Solutions/therapeutic use , Isotonic Solutions/therapeutic use , Gastrointestinal Tract , Feces , Administration, Intravenous/veterinary
11.
Clin. biomed. res ; 42(4): 334-341, 2022.
Article in English | LILACS | ID: biblio-1513203

ABSTRACT

Introduction: Pediatric oncology patients have a limited number of venous access routes and need a large number of drugs during hospitalization. This study evaluates potential medication incompatibilities (MI) in pediatric oncology prescriptions and identifies possible factors associated with the risk of their occurrence. Methods: This cross-sectional study evaluated prescriptions from a tertiary universitary hospital from December 2014 to December 2015. The association between variables and the risk of potential incompatibilities between drugs was determined by Student's t-test and Pearson's chi-square, considering p < 0.05 significant. The odds ratio was calculated considering a 95% confidence interval for each drug. Results: 385 prescriptions were evaluated. The mean age of 124 patients was 9.22 years old (SD = ± 5.10), and 50.65% were male. The most frequent diagnosis and reason for hospitalization were leukemia (27.30%) and chemotherapy (36.10%). The totally implantable catheter was the most commonly used venous access (61.30%). In 87.5% of prescriptions, there was the possibility of MI, and 2108 incompatibilities were found, considering 300 different combinations between two drugs. Age, diagnosis, reason for hospitalization, and type of venous access were risk factors for potential incompatibilities (p < 0.05). The following drugs present higher risk of potential incompatibilities: leucovorin, sodium bicarbonate, cefepime, diphenhydramine, dimenhydrinate, hydrocortisone, and ondansetron, with a significant odds ratio. Conclusion: The possibility of MI in prescriptions for pediatric oncology patients is frequent. Thus, the identification of risk factors may contribute to patient safety and to the rational use of drugs.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Pediatrics , Drug Utilization/statistics & numerical data , Inappropriate Prescribing , Administration, Intravenous , Neoplasms/drug therapy , Cross-Sectional Studies , Drug-Related Side Effects and Adverse Reactions/epidemiology
12.
Braz. J. Pharm. Sci. (Online) ; 58: e191124, 2022. tab
Article in English | LILACS | ID: biblio-1394054

ABSTRACT

Abstract Snakebite is one of the major health issues posing considerable morbidity and mortality. According to an estimate of World Health Organization (WHO) (World health organization, 2021) approximately 5 million people are bitten by several species of snakes resulting in up to 2.5 million envenomation cases annually. The mainstay of treatment for envenomation is intravenous administration of anti-snake venom. Although antivenom neutralizes the systemic effects but it does not relieve the symptoms such as venom-induced hemorrhage, necrosis and nephrotoxicity. Moreover, the use of antivenoms is associated with hypersensitivity reactions including urticaria, anaphylaxis, or serum sickness due to their heterologous property. Furthermore, stringent storage conditions and narrow specificity of antivenoms limit their use in both developed as well as developing countries. In this context, researchers have been searching for natural products and plant extracts to explore their antivenom activity along with anti-myotoxic, anti-hemorrhagic and anti-inflammatory properties. Plant remedies may prove to be an effective alternate for antivenom sera with less adverse events and better tolerability. To the best of our knowledge, this is the first comprehensive review of medicinal plants possessing anti-snake venom activities against certain species of snakes. The current review highlights the investigated plants with their phytochemical analysis to integrate the available information for future research and development of antivenom sera.


Subject(s)
Plants, Medicinal/adverse effects , Snake Venoms/analysis , Antivenins/analysis , Elapid Venoms/isolation & purification , Phytochemicals/agonists , Snake Bites/classification , World Health Organization , Plant Extracts , Administration, Intravenous/instrumentation
13.
Rev. Soc. Bras. Clín. Méd ; 19(2): 116-119, abr.-jun. 2021.
Article in Portuguese | LILACS | ID: biblio-1379284

ABSTRACT

A dor abdominal no paciente com lúpus eritematoso sistêmico tem amplo espectro clínico, variando desde condições inespecí- ficas, como diarreia e vômitos, até eventos de importante morbi- mortalidade, como o abdome agudo inflamatório e/ou perfura- tivo. A seguir, descreve-se um caso de paciente do sexo feminino, de 23 anos, internada por dor abdominal associada a vômitos e à diarreia crônica e progressiva. Foi diagnosticada com lúpus eritematoso sistêmico há 2 anos. Durante a internação, evoluiu com quadro de abdome agudo, e foi realizada tomografia compu- tadorizada de abdome, revelando importante edema de parede intestinal difuso. Isso, somado a alterações clínico-laboratoriais, permitiu o diagnóstico de enterite lúpica. Foi realizado tratamen- to conservador, com corticoterapia e terapia de suporte com correção de distúrbios eletrolíticos severos, sendo iniciado ciclo- fosfamida, com resolução dos sintomas gastrintestinais.


Abdominal pain in patients with systemic lupus erythematosus has a broad clinical spectrum, ranging from nonspecific symp- toms, such as diarrhea and vomiting, to events of significant morbidity and mortality, such as acute inflammatory and/or per- forating abdomen. This article describes a case of a 23-year-old female patient hospitalized for abdominal pain, associated with vomiting and progressive chronic diarrhea. She was diagnosed with systemic lupus erythematosus 2 years ago. During hospita- lization, the patient progressed with acute abdomen, and an ab- dominal computed tomography scan was performed, revealing major diffuse intestinal wall edema. This, added to clinical and laboratories alterations, allowed the diagnosis of lupus enteritis. A conservative treatment with corticotherapy and supportive therapy with correction of severe electrolyte disturbances were initiated, as well as the prescription of cyclophosphamide, with resolution of gastrointestinal symptoms.


Subject(s)
Humans , Female , Young Adult , Enteritis/etiology , Lupus Erythematosus, Systemic/complications , Vomiting/etiology , Water-Electrolyte Imbalance/therapy , Tomography, X-Ray Computed , Abdominal Pain/etiology , Ultrasonography , Adrenal Cortex Hormones/therapeutic use , Rare Diseases/etiology , Diarrhea/etiology , Enteritis/diagnosis , Enteritis/drug therapy , Administration, Intravenous , Piperacillin, Tazobactam Drug Combination/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use
14.
Chinese Medical Journal ; (24): 2666-2674, 2021.
Article in English | WPRIM | ID: wpr-921171

ABSTRACT

BACKGROUND@#Intravenous thrombolysis (IVT) is an effective way for treating acute ischemic stroke (AIS). However, its effects have not been established among AIS patients with unclear stroke symptoms or with stroke onset for >4.5 h.@*METHODS@#We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials and Google Scholar databases for randomized controlled trials that compared IVT (IVT group) and placebo or usual care (control group [CG]) in AIS patients with disease onset for >4.5 h. The outcomes of interest included the favorable functional outcome (defined as modified Rankin Scale [mRS] scores 0-1) at 90 days, the functional independence (defined as mRS scores 0-2) at 90 days, proportion of patients with symptomatic intracerebral hemorrhage (sICH) and death at 90 days. We assessed the risk of bias using the Cochrane tool. Pre-specified subgroup analyses were performed by age (≤70 years or >70 years), National Institute of Health Stroke Scale (NIHSS, ≤10 or >10) and time window (4.5-9.0 h or >9.0 h).@*RESULTS@#Four trials involving 848 patients were eligible. The risk of bias of included trials was low. Patients in the IVT group were more likely to achieve favorable functional outcomes (45.8% vs. 36.7%; OR 1.48, 95% CI 1.12-1.96) and functional independence (63.8% vs. 55.7%; OR 1.43, 95% CI 1.08-1.90) at 90 days, but had higher risk of sICH (3.0% vs. 0.5%; OR 5.28, 95% CI 1.35-20.68) at 90 days than those in the CG. No significant difference in death at 90 days was found between the two groups (7.0% vs. 4.1%; OR 1.80; 95% CI 0.97-3.34).@*CONCLUSIONS@#Use of IVT in patients with extended time window may improve their functional outcomes at 90 days, although IVT may induce increased risk of sICH. Care of these patients should well balance the potential benefits and harms of IVT.


Subject(s)
Aged , Humans , Administration, Intravenous , Brain Ischemia/drug therapy , Fibrinolytic Agents/therapeutic use , Ischemic Stroke , Stroke/drug therapy , Thrombolytic Therapy , Treatment Outcome
15.
Rev. chil. anest ; 50(5): 685-689, 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1532566

ABSTRACT

BACKGROUND: Cannulation of a peripheral venous access is a routine procedure in pediatric patients admitted to the hospital. 50% of the time cannulation on the first attempt is not feasible, so it is necessary to repeat the puncture, resulting in a complex and frustrating procedure. Half of the children admitted to the hospital have a difficult venous access (DIVA). OBJECTIVE: To carry out a review, which provides information about DIVA in pediatrics, how to evaluate and proceed in these patients. DESIGN: DIVA Score considers vein palpability, vein visibility, age and history of prematurity. The score ranges from 0 to 10 points. Values greater than 4 are associated with difficult venous access. There are associated risk factors: obesity, musculoskeletal malformations, chemotherapy treatment, diabetes mellitus, patients on dialysis, limb edema, moderate to severe dehydration, history of difficult venous access, anxiety of the patient and/or parents report that the child is less likely to cooperate. When making the decision to establish a venous access, it should be evaluated whether it is an emergency or not, the characteristics of the medications and infusions, the time of therapy and the anatomical sites for puncture. Ultrasound and transillumination techniques decrease the time to obtain a venous access and increase the success rate on the first attempt. CONCLUSION: The decision to obtain a venous access must take into account the criteria and risk factors for DIVA. The most recognized scale is the DIVA Score.


INTRODUCCIÓN: La canulación de un acceso venoso periférico es un procedimiento rutinario en los pacientes pediátricos que ingresan al hospital. 50% de las veces la canulación al primer intento es frustra, por lo que es necesario repetir la punción resultando el procedimiento complejo y frustrante. La mitad de los niños que ingresa al hospital presentan un acceso venoso difícil (DIVA, sigla derivada de "difficult intravenous access"). OBJETIVO: Realizar una revisión, que entrega información acerca de DIVA en pediatría, cómo evaluar y proceder en estos pacientes. DESARROLLO: DIVA Score considera palpabilidad y visibilidad venosa, edad y antecedente de prematurez. El puntaje va desde 0 a 10 puntos. Valores mayores a 4 se asocian a acceso venoso difícil. Existen factores de riesgo asociados: obesidad, malformaciones osteomusculares, tratamiento con quimioterapia, diabetes mellitus, pacientes en diálisis, edema de extremidades, deshidratación moderada a severa, historia de acceso venoso difícil, ansiedad del paciente y/o padres que refieren que el niño es poco probable que coopere. Al tomar la decisión de establecer un acceso venoso se debe evaluar si es urgencia o no, las características de los medicamentos e infusiones, tiempo de terapia y los sitios anatómicos para punción. La ultrasonografía y las técnicas de transiluminación disminuyen el tiempo de obtención del acceso venoso e incrementan la tasa de éxito en el primer intento. CONCLUSIÓN: En la decisión de obtener un acceso venoso se deben tener en cuenta los criterios y factores de riesgo de acceso venoso difícil. La escala más reconocida es el DIVA Score.


Subject(s)
Humans , Child , Catheterization, Peripheral/adverse effects , Catheterization, Peripheral/standards , Ultrasonography, Interventional , Decision Making , Administration, Intravenous
16.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 39: e2019365, 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1155471

ABSTRACT

ABSTRACT Objective: To describe two cases of unusual variants of sickle cell disease. Case description: We present two cases of sickle cell disease variants (haemoglobinopathies), from unrelated families, in the state of Balochistan (Pakistan). One was diagnosed with sickle cell disease in the haemoglobin electrophoresis, whereas the other was diagnosed with sickle cell SE disease. Both were diagnosed based on the presentation of osteomyelitis. Comments: Haemoglobin SD disease (Hb SD) and haemoglobin SE disease (Hb SE) are rare haemoglobinopathies in the world. The lack of available literature suggests that both are variants of sickle cell disease (SCD), with heterogeneous nature. The prevalence of sickle cell disease with compound heterozygotes was found at a variable frequency in the population of the Asian Southeast. The frequency of osteomyelitis in SCD is 12 to 18%, but its occurrence among variant haemoglobinopathies is little reported. Both reported cases presented with osteomyelitis as a characteristic of the disease presentation.


RESUMO Objetivo: Descrever dois casos de variantes raras da hemoglobinopatia falciforme. Descrição do caso: Apresentamos aqui dois casos de hemoglobinopatias variantes das células falciformes, de famílias não relacionadas, no estado do Baluchistão (Paquistão), sendo um diagnosticado como doença da hemoglobina SD na eletroforese de hemoglobina, enquanto o outro com doença da hemoglobina SE. Ambos foram diagnosticados a partir da apresentação de osteomielite. Comentários: Hemoglobina SD (Hb SD) e hemoglobina SE (Hb SE) são hemoglobinopatias raras no mundo. A escassez de literatura disponível sugere que ambas são variantes da doença falciforme (DF) com natureza heterogênea. A prevalência de hemoglobinopatia falciforme com heterozigosidade composta foi encontrada com frequência variável na população do sudeste asiático. A frequência de osteomielite na DF é de 12 a 18%, mas sua ocorrência entre as hemoglobinopatias falciformes variantes é pouco relatada. Os dois casos reportados apresentaram osteomielite como característica de apresentação da doença.


Subject(s)
Humans , Male , Female , Child , Osteomyelitis/diagnosis , Blood Protein Electrophoresis/methods , Hemoglobinopathies/genetics , Anemia, Sickle Cell/diagnosis , Anemia, Sickle Cell/genetics , Osteomyelitis/etiology , Osteomyelitis/drug therapy , Pakistan/ethnology , Magnetic Resonance Imaging/methods , Radiography/methods , Mass Screening/standards , Mass Screening/ethics , Prevalence , Administration, Oral , Treatment Outcome , Administration, Intravenous , Hemoglobinopathies/diagnosis , Hemoglobinopathies/blood , Heterozygote , Hydroxyurea/administration & dosage , Hydroxyurea/therapeutic use , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/epidemiology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antisickling Agents/administration & dosage , Antisickling Agents/therapeutic use
17.
Braz. J. Pharm. Sci. (Online) ; 57: e18910, 2021. tab, graf
Article in English | LILACS | ID: biblio-1345454

ABSTRACT

Chemotherapy induced nausea and vomiting (CINV) is an issue, which usually occurs in cancer patient. Despite high bioavailability of oral and intravenous administration, these have some drawbacks. The oral route causes hepatic first pass metabolism and intravenous route is invasive in nature. Hence, antiemetic drug by means of transdermal route is necessary to administer in such cases. The aim of the present investigation is to develop suitable Transdermal Therapeutic System (TTS) with an objective to enhance solubility and skin permeability properties of metoclopramide base. Preformulation study begins with an approach to enhance solubility of 40 metoclopramide base by solid dispersion technique. transdermal films were prepared with 41 the solid dispersion as well as with pure drug. Phase solubility study at various temperatures reveals binding constants (Ka, 95-350 M-1 for PVP K30; 56-81 M-1 for HPßCD). Spontaneity of solubilization was justified by AL type linear profiles. The films showed satisfactory diffusion (%), permeation rate and flux after 8 h study. The transdermal patches as prepared were analyzed under FTIR, DSC and SEM. Both solubility and permeability rate in this investigation have been enhanced. So, it can be affirmed that this route would effectively enhance bioavailability


Subject(s)
Solubility , Metoclopramide/antagonists & inhibitors , Patients/classification , Pharmaceutical Preparations/administration & dosage , Biological Availability , Spectroscopy, Fourier Transform Infrared , Diffusion/drug effects , Drug Therapy , Administration, Intravenous/instrumentation , Motion Pictures , Neoplasms/pathology
18.
Investig. enferm ; 23(1)2021. b: 1Tab ; b: 1graf
Article in Spanish | LILACS, BDENF, COLNAL | ID: biblio-1371671

ABSTRACT

Los medicamentos que son administrados erróneamente pueden producir efectos adversos, los cuales pueden causar afectaciones en el paciente y gastos adicionales en las instituciones. Los cuatro errores más comunes en la administración de medicamentos por vía intravenosa son dosis incorrectas del medicamento, volumen incorrecto, mezclas incorrectas e incompatibilidad farmacológica. El nivel de conocimiento farmacológico en el profesional de enfermería cobra especial importancia. Objetivo: analizar la literatura disponible sobre estrategias utilizadas para prevenir la ocurrencia de estos errores en la administración de medicamentos intravenosos por parte del personal enfermería desde el año 2010 al 2019. Método: se realizó una revisión integrativa (RI) para dar respuesta a la pregunta: ¿cuál es la evidencia disponible sobre estrategias para la prevención de errores en la administración de medicamentos por vía intravenosa? Se utilizaron bases datos entre las que se encuentran OVID, ScienceDirect, SciELO, Medline Complete, Academic Search Complete, PubMed y Guías de Prácticas Clínicas, con límite de tiempo entre 2010 y 2019. Resultado: se identificaron 17 publicaciones sobre estrategias de prevención de errores en la administración de medicamentos por vía Intravenosa, se clasificaron los resultados en 3 grupos relacionados con dosis, volumen, mezclas e incompatibilidades y con factores extrínsecos del paciente. Conclusiones: el número de estudios en cuanto a la prevención de errores en la administración de los medicamentos intravenosos es reducido al igual que el rigor metodológico; respecto a las estrategias de minimización de errores, prevalece la utilización de dispositivos electrónicos (bombas inteligentes, códigos electrónicos, etiquetado), comunicación asertiva, creación y adherencia a las guías y protocolos (principalmente en fármacos analgésicos y antibióticos) , fortalecimiento de los conocimientos individuales (educación continua, temas farmacológicos y capacitación en habilidades técnicas) y la generación de una estandarización en la preparación y administración de medicamentos intravenosos.


Erroneous intravenous medication administration can produce adverse effects, which can cause affectations in the patient and additional expenses for the institutions. The four most common errors in intravenous medication administration are wrong doses, wrong volume, wrong mixes, and pharmacological incompatibility. The level of pharmacological knowledge in nursing professionals is essential. Objective: to analyze the available literature on strategies used to prevent these errors in the administration of intravenous medications by nursing staff from 2010 to 2019. Method: an integrative review (IR) was carried out to answer the question: what is the available evidence on strategies for preventing errors in the administration of intravenous medication? Databases were used, including OVID, ScienceDirect, SciELO, Medline Complete, Academic Search Complete, PubMed, and Clinical Practice Guidelines, with a period limit between 2010 and 2019. Results: 17 publications were identified on strategies for preventing errors in the administration of intravenous medication. The results were classified into 3 groups related to dose, volume, mixtures,and incompatibilitiesand with factorsextrinsicto the patient. Conclusions: the number of studiesregarding the prevention oferrorsissmall,asisthemethodologicalrigor.Regarding thestrategiestominimizeerrors,the use ofelectronic devices prevails (smart pumps, electronic codes, labeling); assertive communication, creation, and adherence to guidelines and protocols (mainly in analgesic drugs and antibiotics); strengthening of individual knowledge (continuing education in pharmacological issues and training in technical skills) and the generation of standardization in the preparation and administration of intravenous medication.


Os medicamentos administrados de forma incorreta podem produzir efeitos adversos, que podem causar afetações no paciente e gastos adicionais nas instituições. Os quatro erros mais comuns na administração intravenosa de medicamentos são doses erradas, volume errado, misturas erradas e incompatibilidade farmacológica. O nível de conhecimento farmacológico do professional de enfermagem é especialmente importante. Objetivo: analisar a literatura disponível sobre as estratégias utilizadas para prevenir a ocorrência desses erros na administração de medicamentos intravenosos por professionais de enfermagem no período de 2010 a 2019. Método: foirealizada umarevisão integrativa(RI) pararesponderà questão:Quaisasevidências disponíveissobreestratégias de prevenção deerros naadministração de medicamentos intravenosos? Foram utilizadas bases de dados,entreas queestao OVID, ScienceDirect, SciELO, Medline Complete, Academic Search Complete, PubMed e Guías de Práticas Clínicas, com limite de tempo entre 2010 e 2019. Resultado: foram identificadas 17 publicações sobre estratégias de prevenção de erros na administração de medicamentos por via intravenosa, os resultados foram classificados em três grupos relacionados a dose, volume, misturas e incompatibilidadeseafatoresextrínsecosao paciente. Conclusões: o número deestudos sobre prevenção deerros naadministração de medicamentos intravenosos é pequeno, assim como o rigor metodológico. Em relação às estratégias para minimizar erros, prevalece o uso de dispositivos eletrônicos (bombas inteligentes, códigos eletrônicos, rotulagem), comunicação assertiva, criação e adesão a diretrizes e protocolos (principalmente em fármacos analgésicos e antibióticos), fortalecimento dos conhecimentos individuais(educação continuada, questõesfarmacológicasetreinamento emhabilidadestécnicas)ea geração de uma padronização no preparo e administração de medicamentos intravenosos.


Subject(s)
Humans , Administration, Intravenous , Patient Safety , Medication Errors
19.
Rev. Soc. Bras. Clín. Méd ; 19(3): 160-164, set 2021.
Article in Portuguese | LILACS | ID: biblio-1391846

ABSTRACT

Objetivo: Avaliar a prevalência e o manejo da hiperglicemia de estresse em pacientes internados em uma unidade de terapia intensiva. Métodos: Estudo retrospectivo, realizado de janeiro a junho de 2018. Os dados foram obtidos a partir de 582 prontuá- rios eletrônicos, considerando os valores glicêmicos durante a hospitalização, história prévia ou não de diabetes mellitus, causas do internamento, tempo de permanência na unidade de terapia intensiva, presença de complicações durante o internamento e conduta utilizada em caso de hiperglicemia de estresse. Resulta- dos: Dos 582 pacientes internados na unidade de terapia intensi- va, 579 tiveram sua glicemia indicada nos prontuários analisados; 341 (58,9%) apresentaram hiperglicemia em algum momento da internação, sendo a hiperglicemia de estresse caracterizada em 200 pacientes (35%). A duração média de internamento desses pacientes foi de 8,39±10,9 dias, e a causa mais frequente de inter- namento foi devido a pós-operatório por diversas causas, somando 148 indivíduos (74%). Dentro os pacientes, 72 (36%) apresenta- ram alguma complicação. Além disso, 13 casos (6,5%) evoluíram para óbito. Conclusão: Estudos disponíveis sobre alvos de gli- cose em pacientes críticos das unidades de terapia intensiva apresentam difícil interpretação devido às diferenças subs- tanciais no grupo de populações e aos protocolos de gestão de pacientes utilizados em vários centros. Todavia, a prevalência da hiperglicemia de estresse encontrada nesta amostra é se- melhante à de outras casuísticas estudadas. O índice eleva- do de complicações enfatiza a necessidade de padronização nos critérios para diagnóstico e tratamento da hiperglicemia de estresse objetivando melhor prognóstico desses pacientes independentemente da causa do internamento.


Objective: To evaluate the prevalence and management of stress hyperglycemia in patients hospitalized in anintensive care unit. Methods: Retrospective study, carried out from January to June 2018. Data were obtained from 582 electronic medical records, considering glycemic values during hospitalization, existence of previous history of Diabetes Mellitus, causes of hospitalization, length of stay in the intensive care unit, presence of complications during hospitalization, and behavior used in case of stress hyper- glycemia. Results: Of the 582 patients admitted in the ICU, 579 had their glycemia indicated in the charts analyzed: 341 (58,9%) had hyperglycemia in a certain moment of hospitalization, with stress hyperglycemia being present in 200 patients (35%). The average duration of hospitalization of these patients was 8,39 ± 10,9 days, and the most frequent cause of hospitalization was postoperative for various causes, totaling 148 individuals (74%). Of the patients, 72 (36%) presented some type of complication and 13 patients (6,5%) died. Conclusion: Available studies on glucose targets in critical intensive care unit patients are difficult to be interpre- ted because of substantial differences in the study populations and of patient management protocols used at various centers. However, the prevalence of stress hyperglycemia found in this sample is similar to that of other study groups. The high com- plication rate emphasizes the need for standardization of the criteria for diagnosis and treatment of stress hyperglycemia aiming at a better prognosis of these patients regardless of the cause of hospitalization.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Stress, Physiological , Hyperglycemia/epidemiology , Intensive Care Units/statistics & numerical data , Postoperative Complications/epidemiology , Blood Glucose/analysis , Clinical Protocols , Prevalence , Cross-Sectional Studies , Retrospective Studies , Hospital Mortality , Diabetes Mellitus/diagnosis , Diabetes Mellitus/etiology , Electronic Health Records/statistics & numerical data , Administration, Intravenous , Glycemic Control , Hospitalization/statistics & numerical data , Hyperglycemia/complications , Hyperglycemia/etiology , Hyperglycemia/drug therapy , Hyperglycemia/blood , Hypoglycemic Agents/administration & dosage , Hypotension/diagnosis , Insulin/administration & dosage
20.
Ciênc. cuid. saúde ; 20: e52102, 2021. graf
Article in Portuguese | LILACS, BDENF | ID: biblio-1339632

ABSTRACT

RESUMO Objetivo: relatar evento adverso no preparo e administração de heparina endovenosa e ações implementadas pela equipe de saúde. Métodos: trata-se de relato de experiência sobre as ações implementadas após análise de evento adverso no preparo e administração de heparina em paciente internado em um Hospital Universitário do Sul do Brasil. Os dados foram coletados nos registros do prontuário do paciente, atas de reuniões das equipes envolvida se do plano de ação das medidas instituídas após evento ocorrido em novembro de 2017. A análise dos resultados foi realizada de forma descritiva e o projeto aprovado por Comitê de Ética em Pesquisa. Resultados: as ações realizadas incluíram a revisão de rotinas e protocolos relacionados ao cálculo de dose, preparo e administração da heparina endovenosa. Houve a inclusão como medicamento de alta vigilância e realização da dupla checagem. Também foram divulgadas orientações e alertas em nível institucional para todos os membros da equipe de enfermagem. Conclusão: a experiência contribuiu para evidenciar a necessidade de monitorar incidentes e seus impactos, encontrar estratégias para reduzi-los por meio de revisões nos processos e implementação de ações na prática assistencial visando maior segurança no preparo e administração de heparina endovenosa.


RESUMEN Objetivo: relatar evento adverso en la preparación y administración de heparina endovenosa y acciones implementadas por el equipo de salud. Métodos: se trata de un relato de experiencia sobre las acciones implementadas tras el análisis de evento adverso en la preparación y administración de heparina en paciente ingresado en un Hospital Universitario del Sur de Brasil. Los datos fueron recolectados en los registros médicos del paciente, actas de reuniones de los equipos involucrados y del plan de acción de las medidas instituidas tras el evento ocurrido en noviembre de 2017. El análisis de los resultados fue realizado de forma descriptiva y el proyecto aprobado por Comité de Ética en Investigación. Resultados: las acciones realizadas incluyeron la revisión de rutinas y los protocolos relacionados al cálculo de dosis, preparación y administración de heparina endovenosa. Hubo la inclusión como medicamento de alta vigilancia sanitaria y la realización del doble chequeo. También fueron divulgadas orientaciones y alertas a nivel institucional para todos los miembros del equipo de enfermería. Conclusión: la experiencia contribuye para evidenciar la necesidad de monitorear incidentes y sus impactos, encontrar estrategias para reducirlos por medio de revisiones en los procesos y la implementación de acciones en la práctica asistencial con el objetivo de una mayor seguridad en la preparación y administración de heparina endovenosa.


ABSTRACT Objective: to report an adverse event in the preparation and endovenous administration of heparin and actions implemented by the health team. Methods: this is an experience report on the actions implemented after analyzing an adverse event in the preparation and administration of heparin in a patient admitted to a University Hospital in southern Brazil. Data were collected from the patient's medical records, minutes of meetings of the teams involved, and the action plan of the measures instituted after an event that occurred in November 2017. Results were analyzed in a descriptive manner and the project was approved by the Research Ethics Committee. Results: the actions carried out included the review of routines and protocols related to the calculation of dose, preparation, and endovenous administration of heparin. There was inclusion as a high-alert medication and double checking. Institutional-level guidelines and alerts were also released to all members of the nursing team. Conclusion: the experience contributed to highlight the need to monitor incidents and their impacts, find strategies to reduce them through process reviews and implementation of actions in care practice aiming at greater safety in the preparation and endovenous administration of heparin.


Subject(s)
Humans , Male , Female , Heparin , Drug-Related Side Effects and Adverse Reactions , Administration, Intravenous , Patient Care Team , Risk Management , Safety , Pharmaceutical Preparations , Family , Health , Disaster Preparedness , Disease Prevention , Dosage , Patient Safety , Hospitals, University , Medication Errors , Nursing Care
SELECTION OF CITATIONS
SEARCH DETAIL